Roivant Sciences Ltd.
ROIV
$36.36
$0.060.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -33.55% | -66.71% | -77.83% | -64.89% | -72.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.55% | -66.71% | -77.83% | -64.89% | -72.84% |
| Cost of Revenue | 32.16% | 37.38% | 18.50% | 16.10% | 28.72% |
| Gross Profit | -33.10% | -43.12% | -25.12% | -18.75% | -36.03% |
| SG&A Expenses | 25.49% | -23.99% | 32.27% | -34.01% | 41.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.07% | -0.11% | 25.19% | -13.03% | 34.48% |
| Operating Income | -29.55% | -1.27% | -28.71% | 12.33% | -38.69% |
| Income Before Tax | -9.40% | 323.63% | -23.82% | 29.12% | -1,270.99% |
| Income Tax Expenses | -185.14% | 99.41% | 191.25% | -43.85% | -61.14% |
| Earnings from Continuing Operations | -6.10% | 240.96% | -50.14% | 29.89% | -766.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 99.32% | -214.92% | -6.81% | 5.59% | 33.72% |
| Net Income | 15.01% | 246.75% | -256.98% | 50.68% | -334.38% |
| EBIT | -29.55% | -1.27% | -28.71% | 12.33% | -38.69% |
| EBITDA | -29.84% | -3.41% | -29.41% | 12.10% | -39.55% |
| EPS Basic | 19.77% | 247.82% | -262.80% | 46.74% | -353.51% |
| Normalized Basic EPS | 3.84% | -78.70% | -103.08% | -10.83% | -137.77% |
| EPS Diluted | 19.77% | 195.37% | -264.13% | 45.69% | -353.51% |
| Normalized Diluted EPS | 3.84% | -54.44% | -103.08% | -10.83% | -152.63% |
| Average Basic Shares Outstanding | 5.95% | -0.73% | -3.58% | -7.41% | -7.55% |
| Average Diluted Shares Outstanding | 5.95% | 14.84% | -3.58% | -7.41% | -12.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |